3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Nasopharyngeal Carcinoma
26
Prostatic Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Nasopharyngeal Neoplasms
6
Head and Neck Neoplasms
6
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Oropharyngeal Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Tongue Neoplasms
2
Salivary Gland Neoplasms
2
Radiation Injuries
2
Neurotoxicity Syndromes
2
Hypopharyngeal Neoplasms
2
Glioblastoma
2
Carcinoma
2
Brain Neoplasms
2
Astrocytoma
2
Vaginal Neoplasms
1
Thoracic Neoplasms
1
Stage II Prostate Adenocarcinoma AJCC v7
1
Sarcoma
1
Precancerous Conditions
1
Postoperative Complications
1
Papillomavirus Infections
1
Pancreatic Intraductal Neoplasms
1
Pancreatic Adenocarcinoma
1
Ototoxicity
1
Oligodendroglioma
1
Interventions
Oxaliplatin
10
Fluorouracil
7
Leucovorin
6
Gemcitabine
6
Docetaxel
6
Capecitabine
6
Paclitaxel
5
Cisplatin
5
zolbetuximab
4
Ramucirumab
3
Pemetrexed
3
Drug Therapy
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
regorafenib
2
pembrolizumab
2
Vinorelbine
2
Surgical Procedures, Operative
2
Radiotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Cyclophosphamide
2
Chemoradiotherapy
2
Bevacizumab
2
Afatinib
2
vandetanib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Adenocarcinoma
×
Radiotherapy, Intensity-Modulated
×
Clear all
NCT03536182
2021-05-26
CIPHER
University of Texas Southwestern Medical Center
Phase 3
Withdrawn